Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Akero Therapeutics, Inc. | akro-20201231ex321492868.htm |
| EX-31.2 - EX-31.2 - Akero Therapeutics, Inc. | akro-20201231ex3124af347.htm |
| EX-31.1 - EX-31.1 - Akero Therapeutics, Inc. | akro-20201231ex3113fca1e.htm |
| EX-21.1 - EX-21.1 - Akero Therapeutics, Inc. | akro-20201231ex211384978.htm |
| 10-K - 10-K - Akero Therapeutics, Inc. | akro-20201231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-232234 and 333-237220 on Form S-8 of our report dated March 16, 2021 relating to the consolidated financial statements of Akero Therapeutics, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Parsippany, NJ
March 16, 2021